Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saima Sharif

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Cancer|May 12, 2026
Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient surveyUdhayvir S Grewal, Rishi R Patel, Bradley T Loeffler, et al.
Journal of the National Cancer Institute|July 4, 2013
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08Kay Pogue-Geile, Greg Yothers, Yusuke Taniyama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10Laurence E McCahill, Greg Yothers, Saima Sharif, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08Carmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancerCarmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 25, 2023
Biallelic variants in NSUN6 cause an autosomal recessive neurodevelopmental disorderFrancesca Mattioli, Lina Worpenberg, Cai-Tao Li, et al.
Redox Biology|October 6, 2024
A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancerKellie L Bodeker, Brian J Smith, Daniel J Berg, et al.
Cancer Medicine|August 29, 2025
Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal CancerDonghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, et al.
Journal of the National Cancer Institute|September 17, 2015
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical TrialCarmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04Michael J O'Connell, Linda H Colangelo, Robert W Beart, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Cancer|May 12, 2026
Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient surveyUdhayvir S Grewal, Rishi R Patel, Bradley T Loeffler, et al.
Journal of the National Cancer Institute|July 4, 2013
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08Kay Pogue-Geile, Greg Yothers, Yusuke Taniyama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10Laurence E McCahill, Greg Yothers, Saima Sharif, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08Carmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancerCarmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 25, 2023
Biallelic variants in NSUN6 cause an autosomal recessive neurodevelopmental disorderFrancesca Mattioli, Lina Worpenberg, Cai-Tao Li, et al.
Redox Biology|October 6, 2024
A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancerKellie L Bodeker, Brian J Smith, Daniel J Berg, et al.
Cancer Medicine|August 29, 2025
Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal CancerDonghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, et al.
Journal of the National Cancer Institute|September 17, 2015
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical TrialCarmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04Michael J O'Connell, Linda H Colangelo, Robert W Beart, et al.
Pageof 6